Jianwen Guo and colleagues’ trial1 on using FYTF-919 for acute intracerebral haemorrhage has sparked considerable discussion across China's medical community and social media. Although many commend ...

We appreciate the feedback on and constructive criticism of the CHAIN trial,1 where, as in all complex projects, there were various challenges, many of which were unforeseen. The result—an overall ...